Industry

The ad is decided by the sentence you cannot say

One sentence governs every supplement ad. It is what you are allowed to claim the formula does. Get it wrong and you lose the account, not the ad. Here is where that line sits, which openings survive review, why this category is spoken rather than shown, and why a flagged sentence here is a deletion instead of a reshoot.

Flat lay of vitamin bottles with capsules and decorative elements against a green and white backdrop.
Photo by Saul Rivera on Pexels
Creatives that carry spend, per Motion
5-8%
One finished thirty second ad
110 CR
Longest source take accepted
3 min

Structure and function is one sentence. Disease is a different product category.

In the United States a supplement may carry a structure or function claim. It may not carry a disease claim.

The wall between those two is thinner than most brand teams assume.

Supports a healthy inflammatory response sits on one side. Reduces the inflammation of arthritis sits on the other.

That second sentence describes an unapproved drug. It is a different product category with a different regulator.

This is not a preference about tone. It decides whether the account is still running in November.

It also decides who the letter comes from. A platform review is survivable. A regulator is a different afternoon.

Structure and function claims drag a disclaimer with them. The statement has not been evaluated by the Food and Drug Administration, and the product is not intended to diagnose, treat, cure or prevent any disease.

Nobody reads that inside a nine second hook. It has to be legible on screen while the claim is spoken.

That is a creative constraint wearing compliance clothes. Have your own counsel read the wording before it runs. Nothing on this page is legal advice.

If the outcome is off limits, the hook has to be about behaviour

Four openings survive review in this category more often than anything else. They share one property.

None of them makes a promise about a body.

What I stopped buying, and what I replaced it with. What is on the label that nobody reads.

Why I switched after checking the dose. What my third bottle taught me about the first one.

Each of those is a claim about a decision. A regulator cannot falsify what you decided.

A stranger finds a decision more interesting than a benefit statement anyway.

Platforms stack a second rulebook on the first. Health policies commonly block copy implying knowledge of the viewer's condition.

So the direct address that works everywhere else works against you here.

Supplement creative lives or dies on the first sentence. That sentence has fewer legal options than any other category on this list.

  • Openings about your own behaviour survive review more often than openings about outcomes
  • The disclaimer has to be readable on screen while the claim is spoken, not appended at the end
  • Ingredient dose is a factual hook, and one of the few that carries no outcome promise

This is the whole editor

Highlight a phrase and a clip lands on those exact words. No timeline, no keyframes, no layers.

CLIPS · 5I have thisexact conversationeverysingle week. Somebody sits down and says,oh yeah, I takecinnamonevery day.And honestly, doc, I have no idea if it works.So let me tell you what isin that capsule.a clip lands on these wordscut from the editTAKING CINNAMONEVERY DAY?is it doing anythingHeadlineMusicCaptionsTHIS VIDEOLength25.0sClips5Words removed18Export video

The winning format in this category is a person talking, and that is exactly what this makes

Supplements have almost nothing to show. A capsule does not do anything on camera.

The effect is invisible. The packaging shot is interchangeable with every competitor.

So the category has become a spoken one. A person explaining a decision, with footage carrying the world around it.

That is the ad Cutroom is built to produce. Upload one talking-head take of up to three minutes.

It transcribes the read, drafts the cut, places b-roll against the words and returns a finished 9:16 MP4 with captions burned in.

Then you direct it on the transcript. Highlight a phrase and a clip lands over exactly those words.

Delete the line your reviewer flagged and the cut rebuilds around what is left. Change the pace and the whole piece re-cuts.

Coverage caps at 40, 45 or 52 percent depending on pace, so the person holds most of the runtime.

In a category built on trust, that cap is doing more work than it looks like.

From a compliant read to a finished ad

  1. Write the claim line

    Reviewed before filming

  2. One take

    Up to 3 minutes on a phone

  3. Batch

    100 CR: transcript, director pass, b-roll

  4. Cut the flagged line

    Delete, re-cut, export at 20 CR a minute

A flagged line becomes a deletion, not a reshoot

The expensive part of compliance is not the review. It is what happens after it.

One sentence has to come out of a finished video.

In a timeline that means reopening the project and pulling the line. Then re-syncing every caption after it. Then exporting again.

In practice the ad ships late, or it ships with the line still in it.

Here the cut is compiled from the transcript. Remove a sentence and the whole piece rebuilds consistently.

The captions, the clip placement and the timings were never placed by hand, so there is nothing to chase down the track.

That turns the review loop from a production risk into a reading task. It is the only version of compliance that survives a weekly ad schedule.

It also makes variant testing affordable. A finished thirty second ad is about 110 credits.

Twelve compliant openings is roughly 1,320 credits, inside Basic at $39.99 for 2,500 credits a month.

Finished ads a month, by plan

At roughly 110 credits each: 100 for the batch, 20 per output minute to render.

  • Trial, 300 credits2 ads
  • Basic, $39.9922 ads
  • Premium, $79.9945 ads
  • Each $15 top-up9 more

Your bottle, your label, your library, and one file at the end

The b-roll search covers millions of free clips. Kitchens, gyms, morning light, people looking tired.

That is the right footage for a decision-led read. It carries the world your customer lives in.

Your bottle, your label and your certificate of analysis come off your own camera. One shot, twenty minutes.

Upload that clip to your workspace library once. Then highlight the phrase where you name the product and it lands over exactly those words.

Swap the clip in any spot afterwards, from your own library or from the free ones.

The disclaimer is a caption decision. Six packs, plus colour, weight, size and position, with per-word emphasis.

So a legible disclaimer while the claim is spoken is a setting rather than a design job.

The flat facts to plan around. Exports are 9:16 MP4. Source takes cap at three minutes. One project makes one finished ad.

Nothing here reviews your claims. Keep your own approval in front of the camera, and use transcript editing when review comes back late.

Questions people ask

Can the tool tell me whether my claim is compliant?
No. It has no view on your wording. Get claims reviewed by your own counsel before filming, then use transcript editing to remove a flagged line in seconds if review comes back late.
How do I show the disclaimer?
As on-screen text while the claim is spoken. Caption styling gives you six packs plus colour, weight, size and position, so a legible disclaimer is a caption decision rather than a design job.
Can it show my bottle or my supplement facts panel?
Yes. Film the product once, upload the clip to your workspace library, then highlight the phrase where you name it and the shot lands over those words. One twenty minute session covers every ad afterwards.
Who should not buy this?
Brands whose creative is macro product shots and clinical graphics with nobody speaking. For decision-led spoken ads, which is what survives review here, nothing turns a flagged line around faster.

Delete the flagged sentence and the whole cut rebuilds around it before the meeting ends. Every other route in this category calls that a reshoot.

Start with one take300 free credits · no card · cancel anytime